JP2011509252A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011509252A5 JP2011509252A5 JP2010541101A JP2010541101A JP2011509252A5 JP 2011509252 A5 JP2011509252 A5 JP 2011509252A5 JP 2010541101 A JP2010541101 A JP 2010541101A JP 2010541101 A JP2010541101 A JP 2010541101A JP 2011509252 A5 JP2011509252 A5 JP 2011509252A5
- Authority
- JP
- Japan
- Prior art keywords
- stereoisomer
- tautomer
- indazol
- aminocarbonyl
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- CXPSLSYYWGMRQH-MZQXSLHISA-N (e)-but-2-enedioate;2-[4-[(3s)-piperidin-1-ium-3-yl]phenyl]indazole-7-carboxamide Chemical compound [O-]C(=O)\C=C\C([O-])=O.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1 CXPSLSYYWGMRQH-MZQXSLHISA-N 0.000 claims 2
- MYGUDASFCHBTGF-XZPBZCASSA-N 2-[4-[(3s)-piperidin-1-ium-3-yl]phenyl]indazole-7-carboxamide;sulfate Chemical compound [O-]S([O-])(=O)=O.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1 MYGUDASFCHBTGF-XZPBZCASSA-N 0.000 claims 2
- ACNPUCQQZDAPJH-FMOMHUKBSA-N 4-methylbenzenesulfonic acid;2-[4-[(3s)-piperidin-3-yl]phenyl]indazole-7-carboxamide;hydrate Chemical compound O.CC1=CC=C(S([O-])(=O)=O)C=C1.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1 ACNPUCQQZDAPJH-FMOMHUKBSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 claims 2
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 claims 2
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims 2
- PLECLGHOBYKOQA-XZPBZCASSA-N butanedioate;2-[4-[(3s)-piperidin-1-ium-3-yl]phenyl]indazole-7-carboxamide Chemical compound [O-]C(=O)CCC([O-])=O.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1 PLECLGHOBYKOQA-XZPBZCASSA-N 0.000 claims 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 claims 2
- ORZMSMCZBZARKY-UHFFFAOYSA-N 1,3,2$l^{6}-benzodioxathiole 2,2-dioxide Chemical compound C1=CC=C2OS(=O)(=O)OC2=C1 ORZMSMCZBZARKY-UHFFFAOYSA-N 0.000 claims 1
- LCPFHXWLJMNKNC-PFEQFJNWSA-N 4-methylbenzenesulfonate;2-[4-[(3s)-piperidin-1-ium-3-yl]phenyl]indazole-7-carboxamide Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1.N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCC[NH2+]C1 LCPFHXWLJMNKNC-PFEQFJNWSA-N 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 206010057430 Retinal injury Diseases 0.000 claims 1
- 206010038997 Retroviral infections Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical group O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 claims 1
- SBRRKNDQFQNEJP-FFAASGSZSA-N benzene 2-[4-[(3S)-piperidin-1-ium-3-yl]phenyl]indazole-7-carboxamide sulfate Chemical compound [O-]S([O-])(=O)=O.c1ccccc1.NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCC[NH2+]C1.NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCC[NH2+]C1 SBRRKNDQFQNEJP-FFAASGSZSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 239000002534 radiation-sensitizing agent Substances 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 230000037380 skin damage Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229960004964 temozolomide Drugs 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical group CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1033308P | 2008-01-08 | 2008-01-08 | |
| US61/010,333 | 2008-01-08 | ||
| PCT/GB2009/000041 WO2009087381A1 (en) | 2008-01-08 | 2009-01-08 | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011509252A JP2011509252A (ja) | 2011-03-24 |
| JP2011509252A5 true JP2011509252A5 (https=) | 2012-02-16 |
| JP5989965B2 JP5989965B2 (ja) | 2016-09-07 |
Family
ID=40404013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010541101A Active JP5989965B2 (ja) | 2008-01-08 | 2009-01-08 | ２−｛４−［（３ｓ）−ピペリジン−３−イル］フェニル｝−２ｈ−インダゾール−７−カルボキサミドの薬学的に許容される塩 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US8436185B2 (https=) |
| EP (1) | EP2240466B1 (https=) |
| JP (1) | JP5989965B2 (https=) |
| KR (1) | KR101653548B1 (https=) |
| CN (2) | CN101932572A (https=) |
| AU (1) | AU2009203598B2 (https=) |
| BR (1) | BRPI0906020A2 (https=) |
| CA (1) | CA2711491C (https=) |
| ES (1) | ES2548131T3 (https=) |
| FR (1) | FR18C1020I2 (https=) |
| IL (1) | IL206201A (https=) |
| MX (1) | MX337421B (https=) |
| NL (1) | NL300938I2 (https=) |
| NZ (1) | NZ586675A (https=) |
| WO (1) | WO2009087381A1 (https=) |
| ZA (1) | ZA201003902B (https=) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2599458T3 (es) | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| EP2408300B1 (en) | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| EP4166558A1 (en) | 2010-02-12 | 2023-04-19 | Pfizer Inc. | Salts and polymorphs of 8-fluoro-2-{4- [(methylamino)methyl]phenyl}-1 ,3,4,5-tetrahydro-6h-azepino[5,4,3- cd]indol-6-one |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| SG11201610500WA (en) | 2014-06-17 | 2017-01-27 | Vertex Pharma | Method for treating cancer using a combination of chk1 and atr inhibitors |
| FI3277321T3 (fi) | 2015-04-01 | 2024-10-31 | Anaptysbio Inc | T-soluimmunoglobuliinia ja musiiniproteiini 3:a (tim-3) vastaan suunnattuja vasta-aineita |
| AU2016331955B2 (en) | 2015-09-30 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors |
| WO2017056498A1 (ja) * | 2015-09-30 | 2017-04-06 | 国立大学法人東北大学 | 糖尿病性腎症の判定マーカー |
| SG11201811564QA (en) | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| UA124972C2 (uk) * | 2016-07-29 | 2021-12-22 | Янссен Фармацевтика Нв | Способи лікування раку передміхурової залози |
| CN107663190B (zh) * | 2016-07-29 | 2020-06-09 | 钟桂发 | 一种尼拉帕尼及其中间体的制备方法以及中间体化合物 |
| CN106432057A (zh) * | 2016-09-17 | 2017-02-22 | 青岛云天生物技术有限公司 | 一种制备(3s)‑3‑(4‑氨基苯基)哌啶‑1‑甲酸叔丁酯的方法 |
| MX2019005116A (es) | 2016-11-01 | 2019-11-12 | Anaptysbio Inc | Anticuerpos dirigidos contra la proteina de inmunoglobulina de linfocitos t y de mucina 3 (tim-3). |
| JP2019533458A (ja) | 2016-11-01 | 2019-11-21 | アナプティスバイオ インコーポレイティッド | プログラム死１（ｐｄ−１）に対する抗体 |
| WO2018122168A1 (en) | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| WO2018129553A1 (en) | 2017-01-09 | 2018-07-12 | Tesaro, Inc. | Methods of treating cancer with anti-tim-3 antibodies |
| AU2018206481B2 (en) | 2017-01-09 | 2025-02-27 | Tesaro, Inc. | Methods of treating cancer with anti-PD-1 antibodies |
| KR20190130625A (ko) * | 2017-03-27 | 2019-11-22 | 테사로, 인코포레이티드 | 니라파립 제제 |
| CN110944638A (zh) * | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| EP3606524B1 (en) * | 2017-04-04 | 2021-12-01 | Combiphos Catalysts, Inc. | Deuterated (s)-2-(4-(piperidin-3-yl)phenyl)-2h-indazole-7-carboxamide |
| HUE060460T2 (hu) | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| MA48475A (fr) | 2017-04-24 | 2020-03-04 | Tesaro Inc | Procédés de fabrication de niraparib |
| SG11201909395TA (en) | 2017-04-27 | 2019-11-28 | Tesaro Inc | Antibody agents directed against lymphocyte activation gene-3 (lag-3) and uses thereof |
| TW202444417A (zh) | 2017-05-09 | 2024-11-16 | 美商提薩羅有限公司 | 治療癌症的組合療法 |
| KR20200005662A (ko) | 2017-05-18 | 2020-01-15 | 테사로, 인코포레이티드 | 암을 치료하기 위한 조합 요법 |
| CN108530425A (zh) * | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| CN109081828B (zh) | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| HUE062956T2 (hu) | 2017-08-14 | 2023-12-28 | Teva Pharmaceuticals Int Gmbh | Eljárások niraparib és köztitermékei elõállítására |
| CN111094981B (zh) * | 2017-09-13 | 2024-04-16 | B.R.A.H.M.S有限公司 | Pct和pro-adm作为监测抗生素治疗的标记物 |
| CA3075440A1 (en) * | 2017-09-13 | 2019-03-21 | B.R.A.H.M.S Gmbh | Pro-adm as a therapy monitoring marker for critcally ill patients |
| US20200271666A1 (en) * | 2017-09-13 | 2020-08-27 | B.R.A.H.M.S Gmbh | Proadrenomedullin as indicator for renal replacement therapy in critically ill patients |
| TWI843707B (zh) | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| MX2020003770A (es) | 2017-09-30 | 2020-07-29 | Tesaro Inc | Terapias de combinacion para tratar cancer. |
| EA202090655A1 (ru) | 2017-10-06 | 2020-12-07 | Тесаро, Инк. | Комбинированные терапевтические средства и их применение |
| US20210106574A1 (en) | 2017-12-27 | 2021-04-15 | Tesaro, Inc. | Methods of Treating Cancer |
| CN111918667A (zh) | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
| TWI852940B (zh) | 2018-09-04 | 2024-08-21 | 美商泰沙羅公司 | 治療癌症之方法 |
| JP2022504228A (ja) * | 2018-10-03 | 2022-01-13 | テサロ， インコーポレイテッド | ニラパリブ遊離塩基の結晶形態 |
| CN113166071B (zh) * | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
| WO2020072860A1 (en) | 2018-10-05 | 2020-04-09 | Johnson Matthey Public Limited Company | Niraparib solid state form |
| WO2020225753A2 (en) | 2019-05-06 | 2020-11-12 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN110407704B (zh) * | 2019-08-19 | 2022-05-17 | 常州沃腾化工科技有限公司 | 一种3-甲酰基-2-硝基苯甲酸甲酯的合成方法 |
| TWI905184B (zh) | 2020-05-08 | 2025-11-21 | 比利時商健生藥品公司 | 用醋酸阿比特龍和尼拉帕尼之組合治療前列腺癌 |
| JP2024525881A (ja) | 2021-07-19 | 2024-07-12 | ヤンセン ファーマシューティカ エヌ．ベー． | ニラパリブ（ｎｉｒａｐａｒｉｂ）による転移性去勢抵抗性前立腺癌の治療 |
| CA3243120A1 (en) | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF) |
| US20250352534A1 (en) | 2022-02-15 | 2025-11-20 | Tesaro, Inc. | Use of Niraparib for the Treatment of Brain Cancer |
| CN121311226A (zh) | 2023-05-17 | 2026-01-09 | 特沙诺有限公司 | 聚adp核糖聚合酶(parp)抑制剂在治疗癌症中的新用途 |
| WO2025027138A1 (en) | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
| CN117843713A (zh) * | 2023-12-18 | 2024-04-09 | 上海亲合力生物医药科技股份有限公司 | 基于肿瘤微环境激活的激酶抑制剂、组合物及应用 |
| CN119707921B (zh) * | 2024-12-19 | 2026-03-03 | 四川轻化工大学 | 一种尼拉帕尼的合成方法 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9404485D0 (en) | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
| AT401651B (de) * | 1994-06-14 | 1996-11-25 | Biochemie Gmbh | 7-(2-(2-aminothiazol-4-yl)-2-(z)- hydroximinoacetamido)-3-n,n- dimethylcarbamoyloxymethyl-3-cephem-4- |
| EP0841924B1 (en) | 1995-08-02 | 2002-10-02 | Newcastle University Ventures Limited | Benzimidazole compounds |
| CA2332279A1 (en) | 1998-05-15 | 1999-11-25 | Jia-He Li | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
| EP1124805B1 (de) | 1998-10-30 | 2003-05-21 | Lonza AG | Verfahren zur herstellung von 4-[(2',5'-diamino-6'-halogenpyrimidin-4'-yl)amino]-cyclopent-2-enylmethanolen |
| IL142917A0 (en) | 1998-11-03 | 2002-04-21 | Basf Ag | Substituted 2-phenylbenzimidazoles, the production thereof and their use |
| HRP20010451A2 (en) | 1998-11-17 | 2003-04-30 | Basf Ag | 2-phenylbenzimidazoles and 2-phenylindoles, and production and use thereof |
| TR200101498T2 (tr) | 1998-11-27 | 2001-11-21 | Basf Aktiengesellschaft | İkameli benzimidazoller ve parp inhibitörleri olarak kullanımları |
| DE19918211A1 (de) | 1999-04-22 | 2000-10-26 | Basf Ag | Cycloalkylsubstituierte Benzimidazole, deren Herstellung und Anwendung |
| DE19920936A1 (de) | 1999-05-07 | 2000-11-09 | Basf Ag | Heterozyklisch substituierte Benzimidazole, deren Herstellung und Anwendung |
| AU7314200A (en) | 1999-09-17 | 2001-04-24 | Yamanouchi Pharmaceutical Co., Ltd. | Benzimidazole derivatives |
| US6508365B1 (en) * | 1999-12-28 | 2003-01-21 | Pitney Bowes Inc. | Method of removing mail from a mailstream using an incoming mail sorting apparatus |
| DE50112961D1 (de) | 2000-02-01 | 2007-10-18 | Abbott Gmbh & Co Kg | Heterozyklische verbindungen und deren anwendung als parp-inhibitoren |
| DE10022925A1 (de) | 2000-05-11 | 2001-11-15 | Basf Ag | Substituierte Indole als PARP-Inhibitoren |
| JPWO2002068407A1 (ja) | 2001-02-28 | 2004-06-24 | 山之内製薬株式会社 | ベンゾイミダゾール化合物 |
| WO2003007959A1 (en) | 2001-07-16 | 2003-01-30 | Fujisawa Pharmaceutical Co., Ltd. | Quinoxaline derivatives which have parp inhibitory action |
| WO2003062234A1 (en) | 2002-01-23 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Quinoxaline compounds |
| US20040034078A1 (en) | 2002-06-14 | 2004-02-19 | Agouron Pharmaceuticals, Inc. | Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| JPWO2004014861A1 (ja) | 2002-08-09 | 2005-12-02 | 杏林製薬株式会社 | ４−置換キノリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| ATE411980T1 (de) * | 2003-07-21 | 2008-11-15 | Smithkline Beecham Corp | (2s,4s)-4-fluor-1-ä4-fluor-beta-(4-fluorphenyl) l-phenylalanylü-2-pyrrolidincarbonitril-p- toluolsulfonsäuresalz und wasserfreie kristalline formen davon |
| WO2005047290A2 (en) * | 2003-11-11 | 2005-05-26 | Cellular Genomics Inc. | Imidazo[1,2-a] pyrazin-8-ylamines as kinase inhibitors |
| GB0327740D0 (en) * | 2003-11-28 | 2003-12-31 | Glaxo Group Ltd | Novel compounds |
| WO2005066136A1 (en) | 2003-12-22 | 2005-07-21 | Eli Lilly And Company | Bicyclic derivatives as ppar modulators |
| PT1794163E (pt) | 2004-09-22 | 2010-03-01 | Pfizer | Método para a preparação de inibidores de poli(adpribose)- polimerases |
| EP1812439B2 (en) * | 2004-10-15 | 2017-12-06 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP3701964B1 (ja) * | 2005-03-08 | 2005-10-05 | アステラス製薬株式会社 | キヌクリジン誘導体の新規な塩 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| US7728026B2 (en) | 2005-04-11 | 2010-06-01 | Abbott Laboratories, Inc. | 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors |
| US7930013B2 (en) | 2005-06-29 | 2011-04-19 | Compumedics Limited | Sensor assembly with conductive bridge |
| JP5227796B2 (ja) | 2005-09-29 | 2013-07-03 | アボット・ラボラトリーズ | ２位においてフェニルによって置換された１ｈ−ベンズイミダゾール−４−カルボキサミドは強力なｐａｒｐ阻害薬である |
| JP5162465B2 (ja) | 2005-11-15 | 2013-03-13 | アボット・ラボラトリーズ | 置換１ｈ−ベンズイミダゾール−４−カルボキサミド類は強力なｐａｒｐ阻害薬である |
| CA2647545C (en) | 2006-04-03 | 2016-02-23 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| MX2008014004A (es) | 2006-05-02 | 2008-11-12 | Abbott Lab | 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes. |
| TW200801513A (en) | 2006-06-29 | 2008-01-01 | Fermiscan Australia Pty Ltd | Improved process |
| US7892667B2 (en) * | 2006-09-13 | 2011-02-22 | Altek Corporation | Battery security device |
| JP4611444B2 (ja) * | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| JP2008228154A (ja) * | 2007-03-15 | 2008-09-25 | Fujitsu Ltd | 表示装置，および遠隔操作装置 |
-
2009
- 2009-01-08 KR KR1020107015011A patent/KR101653548B1/ko active Active
- 2009-01-08 AU AU2009203598A patent/AU2009203598B2/en active Active
- 2009-01-08 CN CN2009801018616A patent/CN101932572A/zh active Pending
- 2009-01-08 US US12/811,922 patent/US8436185B2/en active Active
- 2009-01-08 WO PCT/GB2009/000041 patent/WO2009087381A1/en not_active Ceased
- 2009-01-08 ES ES09700579.7T patent/ES2548131T3/es active Active
- 2009-01-08 EP EP09700579.7A patent/EP2240466B1/en active Active
- 2009-01-08 NZ NZ586675A patent/NZ586675A/en unknown
- 2009-01-08 CA CA2711491A patent/CA2711491C/en active Active
- 2009-01-08 CN CN201610345956.4A patent/CN106008460B/zh active Active
- 2009-01-08 JP JP2010541101A patent/JP5989965B2/ja active Active
- 2009-01-08 BR BRPI0906020-0A patent/BRPI0906020A2/pt not_active Application Discontinuation
- 2009-01-08 MX MX2010006593A patent/MX337421B/es active IP Right Grant
-
2010
- 2010-06-01 ZA ZA2010/03902A patent/ZA201003902B/en unknown
- 2010-06-06 IL IL206201A patent/IL206201A/en active Protection Beyond IP Right Term
-
2018
- 2018-05-14 FR FR18C1020C patent/FR18C1020I2/fr active Active
- 2018-05-15 NL NL300938C patent/NL300938I2/nl unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011509252A5 (https=) | ||
| JP2010515715A5 (https=) | ||
| JP2023503309A5 (https=) | ||
| AU2020204571A1 (en) | Pyrazole derivatives as sGC stimulators | |
| US10047095B2 (en) | sGC stimulators | |
| NZ710575A (en) | Pharmaceutical compositions for the treatment of diabetes mellitus | |
| JP2010536842A5 (https=) | ||
| EA032028B1 (ru) | СТИМУЛЯТОРЫ рГЦ | |
| JP2014516942A5 (https=) | ||
| AU2017292818B2 (en) | Solid forms of an sGC stimulator | |
| JP2013542261A5 (https=) | ||
| JP2013507408A5 (https=) | ||
| WO2007087241A3 (en) | Treatment of ischemic disease using thrombopoietin | |
| US20240228520A9 (en) | Phosphorus prodrugs of pyrazolo-substituted pyrimidine sgc stimulators | |
| JP2013166781A5 (https=) | ||
| WO2007145863A3 (en) | Sustained release formulation of naltrexone | |
| JP2012520302A5 (https=) | ||
| JP2016505628A5 (https=) | ||
| JP2018505899A5 (https=) | ||
| US20150342989A1 (en) | Compositions comprising non steroidal anti-inflammatory drugs and methods of use thereof | |
| JP2008031164A5 (https=) | ||
| RU2010133241A (ru) | Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида | |
| JP2004262775A5 (https=) | ||
| JP2012512874A5 (https=) | ||
| WO2025233319A1 (en) | (1,2,4-triazol-3-yl)-2-pyridyl-1-isoindolinone for use in the treatment of sepsis |